| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 用于在氨基酸氧化酶、精氨酸酶和/或天冬酰胺酶的存在下产生发酵产物的方法 | CN201180065554.4 | 2011-11-15 | CN103797125B | 2016-12-07 | R.普拉塔; A.洛贝; T.弗曼; S.克拉克; E.M.伯丁 |
| 本发明涉及产生发酵产物的方法，其包括：用α-淀粉酶在天冬酰胺酶和/或氨基酸氧化酶的存在下将含淀粉材料液化为糊精；用葡糖淀粉酶将所述糊精糖化为糖；和使用发酵生物发酵所述糖。 | ||||||
| 2 | 通过高丝氨酸生产丙烯酸酯和其它产品的微生物和方法 | CN201280048633.9 | 2012-10-05 | CN103890186A | 2014-06-25 | 徐隽; C·W·桑德斯; P·R·格林; J·E·维拉斯奎茨 |
| 本发明涉及微生物，其使用高丝氨酸和2-酮基-4-羟基丁酸酯作为中间体来将碳源转化为丙烯酸酯或其它期望的产品。本发明提供进行所述转化的经基因工程化的微生物，以及通过培养所述微生物来生产丙烯酸酯的方法。还提供将高丝氨酸转化为3-羟基丙酰-CoA、3-羟基丙酸酯(3HP)、聚-3-羟基丙酸酯和1,3-丙二醇的微生物和方法。 | ||||||
| 3 | 用于在氨基酸氧化酶、精氨酸酶和/或天冬酰胺酶的存在下产生发酵产物的方法 | CN201180065554.4 | 2011-11-15 | CN103797125A | 2014-05-14 | R.普拉塔; A.洛贝; T.弗曼; S.克拉克; E.M.伯丁 |
| 本发明涉及产生发酵产物的方法，其包括：用α-淀粉酶在天冬酰胺酶和/或氨基酸氧化酶的存在下将含淀粉材料液化为糊精；用葡糖淀粉酶将所述糊精糖化为糖；和使用发酵生物发酵所述糖。 | ||||||
| 4 | 一种黄斑蓝子鱼L-氨基酸氧化酶在毕赤酵母的表达方法及其应用 | CN201410073275.8 | 2014-02-27 | CN103773744A | 2014-05-07 | 黎睿君; 李安兴 |
| 本发明公开了一种毕赤酵母表达黄斑蓝子鱼L-氨基酸氧化酶的方法，它采用基因重组技术将黄斑蓝子鱼L-氨基酸氧化酶基因克隆到表达载体上，构建成表达重组质粒，并转化进入毕赤酵母，组建成表达工程菌，经发酵和表达上清浓缩，获得由毕赤酵母表达的黄斑蓝子鱼L-氨基酸氧化酶粗酶液，该粗酶液对鱼类革兰氏阳性病原菌(无乳链球菌)和革兰氏阴性病原菌(温和气单胞杆菌)具有抑菌作用，可用于后续抗菌制剂的开发。 | ||||||
| 5 | 高フェニルアラニン血症を低減させるように操作された細菌 | JP2017559428 | 2016-05-13 | JP2018515106A | 2018-06-14 | ディーン ファルブ; ビンセント エム イザベラ; ジョナサン ダヴリュー コツラ; ポール エフ ミラー; サラ ロウ; イブ ミレー |
| 遺伝子操作された細菌、その医薬組成物、および高フェニルアラニン血症に関連する疾患をモジュレートおよび治療する方法が開示される。 【選択図】なし |
||||||
| 6 | タンパク質の産生改善のための組成物及び方法 | JP2017508541 | 2015-08-14 | JP2017525359A | 2017-09-07 | エム マドリッド、スーザン |
| 本開示の態様は、例えば、膜結合型銅輸送ATPアーゼ及び可溶性銅トランスポーターなど、宿主細胞での銅輸送に関与する1つ又は2つ以上のタンパク質の発現レベルを操作することによる、宿主細胞から分泌される銅酵素の発現の改良方法に関する。本開示は、そのような改良された宿主細胞と、目的とする1つ又は2つ以上の銅酵素を含む改良された宿主細胞由来の生成物とを含む組成物も提供する。【選択図】図1A | ||||||
| 7 | 糖尿病発症に係る小胞体ストレスに関与する物質のスクリーニング方法 | JP2012556883 | 2012-02-06 | JPWO2012108394A1 | 2014-07-03 | 政一 親泊 |
| 本発明は、ATF6を介した経路の活性化を評価する系を提供することを目的とする。すなわち、本発明は、ATF6を介した経路を活性化する小胞体ストレッサーのスクリーニング方法を提供することを目的とし、さらにはATF6を介した経路の活性化によって引き起こされる小胞体ストレスを抑制する物質のスクリーニング方法、及び抗糖尿病薬候補物質のスクリーニング方法をも提供することをも目的とする。本発明者等は、鋭意研究を重ねた結果、蛍光タンパク質に由来する非蛍光ペプチドドメイン、及びATF6タンパク質ドメインをコードするポリヌクレオチドを用いることにより、ATF6を介した経路の活性化を、生細胞の状態でリアルタイムに且つ高感度に評価できることを見出した。 | ||||||
| 8 | Method for Producing Benzaldehyde | US16032206 | 2018-07-11 | US20180312881A1 | 2018-11-01 | Yasuaki Takakura; Keiko Danjo; Keita Fukui; Sayaka Asari; Takuto Ono |
| A method for producing benzaldehyde is provided. Benzaldehyde is produced from L-phenylalanine or a carbon source by using microorganism(s) having amino acid deaminase, 4-hydroxymandelate synthase, (S)-mandelate dehydrogenase, and benzoylformate decarboxylase. | ||||||
| 9 | Bacteria engineered to treat a disease or disorder | US15319564 | 2016-05-13 | US09889164B2 | 2018-02-13 | Dean Falb; Paul F. Miller; Jonathan W. Kotula; Vincent M. Isabella; Suman Machinani; Adam B. Fisher; Yves Millet |
| Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed. | ||||||
| 10 | COMPOSITIONS AND METHODS FOR IMPROVED PROTEIN PRODUCTION | US15503859 | 2015-08-14 | US20170233746A1 | 2017-08-17 | Susan M. MADRID |
| Aspects of the present disclosure are drawn to methods of improving the expression of secreted cuproenzymes from host cells by manipulating the expression level of one or more proteins involved in copper transport in the host cell, e.g., membrane-bound copper transporting ATPases and soluble copper transporters. The present disclosure also provides compositions containing such improved host cells as well as products derived from the improved host cells that contain one or more cuproenzymes of interest. | ||||||
| 11 | BACTERIA ENGINEERED TO TREAT A DISEASE OR DISORDER | US15319564 | 2016-05-13 | US20170136073A1 | 2017-05-18 | Dean Falb; Paul F. Miller; Jonathan W. Kotula; Vincent M. Isabella; Suman Machinani; Adam B. Fisher; Yves Millet |
| Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed. | ||||||
| 12 | MYCOTOXIN-REDUCING COMPOSITION | US14577567 | 2014-12-19 | US20150150285A1 | 2015-06-04 | STEPHEN PHILIP MANN; DAVID PARFITT |
| A composition comprising an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin. | ||||||
| 13 | METHOD FOR SCREENING SUBSTANCE RELATING TO ENDOPLASMIC RETICULUM STRESS PARTICIPATING IN ONSET OF DIABETES | US13983864 | 2012-02-06 | US20130344530A1 | 2013-12-26 | Seiichi Oyadomari |
| An object of the present invention is to provide a system for evaluating activation of the pathway mediated by ATF6. More specifically, an object of the present invention is to provide a method for screening an endoplasmic reticulum stressor, as well as a method for screening a substance for suppressing an endoplasmic reticulum stress induced by the activation of the pathway mediated by ATF6, and a method for screening an antidiabetic drug candidate. As a result of extensive research, the inventors of the present invention found a method for real-time evaluation of activation of the pathway mediated by ATF6 in viable cells with a high degree of sensitivity. The method uses a nonfluorescent peptide domain derived from a fluorescent protein and a polynucleotide encoding the ATF6 protein domain. | ||||||
| 14 | Method of Preparing a Heat-Treated Product | US13891859 | 2013-05-10 | US20130236598A1 | 2013-09-12 | Gitte Budolfsen; Morten Tovborg Jensen; Hans Peter Heldt-Hansen; Mary Ann Stringer; Lene Lange |
| The formation of acrylamide during heat treatment in the production of a food product is reduced by treating the raw material with an enzyme before the heat treatment. The enzyme is capable of reacting on asparagine or glutamine (optionally substituted) as a substrate or is a laccase or a peroxidase. | ||||||
| 15 | Method of Preparing a Heat-Treated Product | US11952593 | 2007-12-07 | US20080096260A1 | 2008-04-24 | Gitte Budolfsen; Morten Jensen; Hans Heldt-Hansen; Mary Stringer; Lene Lange |
| The formation of acrylamide during heat treatment in the production of a food product is reduced by treating the raw material with an enzyme before the heat treatment. The enzyme is capable of reacting on asparagine as a substrate. | ||||||
| 16 | Method of preparing a heat-treated product | US10530931 | 2003-10-10 | US20060275879A1 | 2006-12-07 | Gitte Lynglev; Morten Jensen; Hans Heldt-Hansen; Mary Stringer; Lene Lange |
| The formation of acrylamide during heat treatment in the production of a food product is reduced by treating the raw material with an enzyme before the heat treatment. The enzyme is capable of reacting on asparagine or glutamine (optionally substituted) as a substrate or is a laccase or a peroxidase. | ||||||
| 17 | Enzymatic powder milk | US644395 | 1984-08-27 | US4617190A | 1986-10-14 | Robert E. Montgomery |
| Aqueous reconstitutible, powder milk incorporates an enzyme system for providing a bacteriostatic effect upon aqueous reconstitution. The enzyme system contains (a) oxidoreductase enzyme that is hydro-interactable with and specific to oxidizable substrate in the powder milk for producing hydrogen peroxide and (b) peroxidatic peroxidase for interacting with the hydrogen peroxide and oxidizable anion from the powder milk to produce, in the reconstituted milk, oxidized anionic bacterial inhibitor. In an illustrative embodiment, powder milk incorporates (a) glucose oxidase that interacts with glucose in powder milk, upon aqueous dilution, to produce hydrogen peroxide and (b) lactoperoxidase for interacting with hydrogen peroxide and, for example the chloride ion from the powder milk to produce, in the reconstituted milk, the hypochlorite ion, a bacterial inhibitor. | ||||||
| 18 | Mycotoxin-reducing composition | US14577567 | 2014-12-19 | US09901108B2 | 2018-02-27 | Stephen Philip Mann; David Parfitt |
| A composition comprising an enzyme, a mycotoxin-binding agent and a microorganism capable of taking up a mycotoxin. | ||||||
| 19 | Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1) | US15510350 | 2015-09-09 | US20170246259A1 | 2017-08-31 | Jeffrey Huang |
| The invention is directed to methods of promoting myelin formation in central nervous system (CNS) tissue in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of interleukin-4 induced gene 1 (IL4-i1) protein. The invention is also directed to methods of monitoring the progression of conditions marked by an impairment of myelin formation in the CNS comprising assessing the levels or activity of IL4-i1 in activated macrophages obtained from the subject. | ||||||
| 20 | BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID | US15379445 | 2016-12-14 | US20170232043A1 | 2017-08-17 | Dean Falb; Paul F. Miller; Yves Millet; Vincent M. Isabella; Jonathan W. Kotula; Alex Tucker |
| The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient's internal environment and respond by turning an engineered metabolic pathway on or off. When turned on, the recombinant bacterial cells complete all of the steps in a metabolic pathway to achieve a therapeutic effect in a host subject. These recombinant bacterial cells are designed to drive therapeutic effects throughout the body of a host from a point of origin of the microbiome. Specifically, the present disclosure provides recombinant bacterial cells comprising a heterologous gene encoding a branched chain amino acid catabolism enzyme. The disclosure further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders involving the catabolism of branched chain amino acids using the pharmaceutical compositions disclosed herein. | ||||||
QQ群二维码
意见反馈
意见反馈